PROCYSBI
Drug
Horizon Pharma plc
Total Payments
$3.7M
Transactions
1,753
Doctors
293
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $282,608 | 270 | 45 |
| 2023 | $242,389 | 334 | 85 |
| 2022 | $242,684 | 325 | 78 |
| 2021 | $214,599 | 157 | 69 |
| 2020 | $213,875 | 112 | 54 |
| 2019 | $228,781 | 238 | 85 |
| 2018 | $445,624 | 138 | 51 |
| 2017 | $1.8M | 179 | 46 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.1M | 33 | 58.7% |
| Honoraria | $1.1M | 477 | 30.1% |
| Consulting Fee | $153,486 | 40 | 4.2% |
| Travel and Lodging | $131,261 | 400 | 3.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $91,690 | 41 | 2.5% |
| Food and Beverage | $34,319 | 762 | 0.9% |
Payments by Type
Research
$2.1M
33 transactions
General
$1.5M
1,720 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 1, OPEN-LABEL, PARALLEL-GROUP, SINGLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS OF PROCYSBI CYSTEAMINE BITARTRATE IN SUBJECTS W ITH NORMAL AND IMPAIRED RENAL FUNCTION | Horizon Pharma plc | $843,613 | 0 |
| A LONG-TERM OPEN-LABEL EXTENSION STUDY OF RP103-MITO-001 TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF CYSTEAMINE BITARTRATE DELAYED-RELEASE CAPSULES RP103 FOR TREATMENT OF CHILDREN WITH INHERITED MITOCHONDRIAL DISEASE | Horizon Pharma plc | $288,585 | 0 |
| HZNP-PRO-IIT-005 | Horizon Pharma plc | $121,347 | 0 |
| A LONG-TERM OPEN-LABEL, SAFETY AND SUPERIOR EFFECTIVENESS STUDY OF CYSTEAMINE BITARTRATE DELAYED-RELEASE CAPSULES RP103 IN PATIENTS WITH CYSTINOSIS | Horizon Pharma plc | $105,654 | 0 |
| HZNP-PRO-IIT-002 | Horizon Pharma plc | $82,500 | 0 |
| AN OPEN-LABEL DOSE-ESCALATING STUDY TO ASSESS THE SAFETY TOLERABILITY EFFICACY PHARMACOKINETICS AND PHARMACODYNAMICS OF CYSTEAMINE BITARTRATE DELAYED-RELEASE CAPSULES RP103 FOR TREATMENT OF CHILDREN WITH INHERITED MITOCHONDRIAL DISEASE | Horizon Pharma plc | $73,061 | 0 |
| AN OPEN-LABEL, DOSE-ESCALATING STUDY TO ASSESS THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF CYSTEAMINE BITARTRATE DELAYED-RELEASE CAPSULES RP103 FOR TREATMENT OF CHILDREN WITH INHERITED MITOCHONDRIAL DISEASE | Horizon Pharma plc | $70,873 | 0 |
| BLOOD BIOMARKERS FOR CYSTINOSIS | Horizon Pharma plc | $68,272 | 0 |
| NAPRTCS Cystinosis Registry | Amgen Inc. | $67,000 | 0 |
| ASSESSING THE ROLE OF THE NLRP3 INFLAMMASOME IN DRIVING INFLAMMATION IN AFFECTED JOINTS OF PATIENTS WITH INTERCRITICAL GOUT | Horizon Therapeutics plc | $53,734 | 0 |
| A LONG-TERM OPEN-LABEL SAFETY AND SUPERIOR EFFECTIVENESS STUDY OF CYSTEAMINE BITARTRATE DELAYED-RELEASE CAPSULES RP103 IN PATIENTS WITH CYSTINOSIS | Horizon Pharma plc | $53,699 | 0 |
| Assessing the role of the NLRP3 inflammasome in driving inflammation in affected joints of patients with intercritical gout | Horizon Therapeutics plc | $40,393 | 0 |
| A LONG-TERM OPEN-LABEL EXTENSION STUDY OF RP103-MITO-001 TO ASSESS THE SAFETY TOLERABILITY AND EFFICACY OF CYSTEAMINE BITARTRATE DELAYED-RELEASE CAPSULES RP103 FOR TREATMENT OF CHILDREN WITH INHERITED MITOCHONDRIAL DISEASE | Horizon Pharma plc | $39,746 | 0 |
| HZNP-PRO-IIT-010 | Horizon Pharma plc | $39,287 | 0 |
| HZNP-PRO-IIT-004 | Horizon Pharma plc | $38,775 | 0 |
| HZNP-PRO-IIT-001 | Horizon Pharma plc | $37,000 | 0 |
| A LONG-TERM OPEN-LABEL SAFETY AND EFFICACY STUDY OF CYSTEAMINE BITARTRATE DELAYED-RELEASE CAPSULES RP103 IN PATIENTS WITH CYSTINOSIS | Horizon Pharma plc | $35,830 | 0 |
| HZNP-PRO-IIT-003 | Horizon Pharma plc | $30,375 | 0 |
| A LONG-TERM, OPEN-LABEL, SAFETY AND EFFICACY STUDY OF CYSTEAMINE BITARTRATE DELAYED-RELEASE CAPSULES RP103 IN PATIENTS WITH CYSTINOSIS | Horizon Pharma plc | $28,655 | 0 |
| A PHASE 1, OPEN-LABEL, SINGLE DOSE, 3 PERIOD RANDOMIZED STUDY TO EVALUATE THE PHARMACOKINETICS OF CYSTEAMINE FOLLOWING ORAL ADMINSTRATION OF PROCYSBI CYSTEAMINE BITARTRATE WITH ORANGE JUICE, WATER, OR OMEPRAZOLE WITH WATER IN HEALTH ADULT SUBJECTS | Horizon Pharma plc | $23,630 | 0 |
Top Doctors Receiving Payments for PROCYSBI — Page 11
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Melanie Gonzalez | Family | Westlake, OH | $19.26 | 1 |
| , M.D | Pediatrics | Cleveland, OH | $19.26 | 1 |
| , D.O | Internal Medicine | Lima, OH | $19.03 | 1 |
| , M.D | Nephrology | Lima, OH | $19.03 | 1 |
| , M.D | Internal Medicine | Lima, OH | $19.03 | 1 |
| , PA-C, RD | Physician Assistant | Austin, TX | $18.85 | 1 |
| , MD | Pediatrics | Moscow, ID | $18.71 | 1 |
| , M.D | Specialist | Charleston, WV | $18.68 | 1 |
| , MD | Nephrology | Charlotte, NC | $18.27 | 1 |
| , MD | Nephrology | Orem, UT | $18.13 | 1 |
| , MD | Orthopaedic Surgery | Windermere, FL | $17.73 | 1 |
| , M.D | Orthopaedic Surgery | Windermere, FL | $17.73 | 1 |
| , MD | Clinical Genetics (M.D.) | Knoxville, TN | $17.41 | 1 |
| Adam Zisman | Pediatrics | Philadelphia, PA | $17.00 | 1 |
| , MD | Pediatrics | Pittsburgh, PA | $17.00 | 1 |
| , M.D | Pediatrics | Loma Linda, CA | $16.54 | 1 |
| , MD | Pediatric Nephrology | San Bernardino, CA | $16.54 | 1 |
| , MD | Pediatric Nephrology | Loma Linda, CA | $16.54 | 1 |
| , MD | Pediatric Nephrology | Dayton, OH | $16.08 | 1 |
| , MD | Hospitalist | Dayton, OH | $16.08 | 1 |
| , MD | Pediatric Nephrology | Dayton, OH | $16.08 | 1 |
| , M.D | Nephrology | Tulsa, OK | $15.95 | 1 |
| Muna Hale | Nephrology | Tulsa, OK | $15.95 | 1 |
| , DO | Nephrology | Tulsa, OK | $15.95 | 1 |
| , M.D | Nephrology | Tulsa, OK | $15.95 | 1 |
Ad
Manufacturing Companies
- Horizon Pharma plc $2.2M
- Horizon Therapeutics plc $1.1M
- Amgen Inc. $282,608
Product Information
- Type Drug
- Total Payments $3.7M
- Total Doctors 293
- Transactions 1,753
About PROCYSBI
PROCYSBI is a drug associated with $3.7M in payments to 293 healthcare providers, recorded across 1,753 transactions in the CMS Open Payments database. The primary manufacturer is Horizon Pharma plc.
Payment data is available from 2017 to 2024. In 2024, $282,608 was paid across 270 transactions to 45 doctors.
The most common payment nature for PROCYSBI is "Unspecified" ($2.1M, 58.7% of total).
PROCYSBI is associated with 20 research studies, including "A PHASE 1, OPEN-LABEL, PARALLEL-GROUP, SINGLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS OF PROCYSBI CYSTEAMINE BITARTRATE IN SUBJECTS W ITH NORMAL AND IMPAIRED RENAL FUNCTION" ($843,613).